1887

oa SA Pharmaceutical Journal - Drug info - new product focus

 

Abstract

Byetta® has been approved for use as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking either metformin or a sulphonylurea or both, and who have not achieved glycaemic control.

Loading

Article metrics loading...

/content/mp_sapj/77/3/EJC82346
2010-04-01
2016-12-06
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error